Zymeworks (ZYME) Short-Term Debt to Capital

Symbol and logo of brand Zymeworks Corp (ZYME)

The development of Zymeworks Inc. (ZYME) relies on the success of zanidatamab and funding from Jazz Pharmaceuticals. This chart reflects a current market value of 0.00. Protein supply chain security is ensured through partnerships with various contractors. Meanwhile, unique antibodies allow the company to exercise pricing power in licensing agreements, attracting significant investment into its research and development.

ZYME (Zymeworks Corp) Current Liabilities to Capital history from 07/04/2022 to 10/28/2026

Analytical breakdowns for Zymeworks Inc.

- price and consensus price forecast:
Price Chart Zymeworks Corp|ZYME - Broker Consensus Forecast
- market capitalization data:
Market Capitalization Zymeworks Inc|ZYME - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Zymeworks|ZYME - Total Stockholders' Equity|Market Value to Book Value Ratio zymeworks.com|ZYME - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Zymeworks Inc.|ZYME - Long-Term Liabilities to Capital|Short-Term Debt to Capital Zymeworks|ZYME - Company Total Indebtedness|Debt to Book Value Zymeworks Inc|ZYME - Long-Term Debt|Company Current Liabilities Zymeworks
Fundamental company analysis:Zymeworks Corp (ZYME)
Manufactured products of zymeworks.com

This ratio measures the proportion of liabilities maturing within one year relative to equity, determining liquidity risk and the degree of dependence on short-term debt financing. For Zymeworks Inc. (ZYME), which attracts multi-billion dollar licensing payments for innovative antibodies, the level of short-term borrowing relative to equity serves as an indicator of the balance between aggressive R&D development and the issuer's financial stability.

Competitors of Zymeworks Inc.

Short-Term Debt to Equity ImmunityBio Corp IBRX|Short-Term Debt to Capital Ratio Immunocore Corp (IMCR)|Janux Therapeutics - Short-Term Debt to Capital|arcusbio.com - Short-Term Debt to Equity Ratio|TNGX (Tango Therapeutics, Inc.) - Short-Term Debt to Equity|IOVA: Current Liabilities to Capital|Immatics Corp (IMTX) - Short-Term Debt to Equity|XNCR (Xencor Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity CMPX (Compass Therapeutics)|Current Liabilities to Capital replimune.com|LYEL: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Innate Pharma SA IPHA|PYXS: Short-Term Debt to Equity Ratio|CGEN - Current Liabilities to Capital|Short-Term Debt to Equity Ratio IO Biotech, Inc. (IOBT)|STRO - Ratio of Short-Term Indebtedness to Capital|MiNK Therapeutics - Short-Term Debt to Capital|HOWL (Werewolf Therapeutics, Inc.) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity IMMX|Short-Term Debt to Equity Ratio ALXO|Short-Term Debt to Equity CUE (Cue Biopharma)|Short-Term Debt to Equity Ratio pdsbiotech.com PDSB|Short-Term Debt to Equity Ratio SONN (Sonnet BioTherapeutics Holdings)|MAIA Biotech - Short-Term Debt to Capital|Liminatus Pharma Corp (LIMN) - Short-Term Debt to Equity|LVTX: Short-Term Debt to Capital Ratio|Short-Term Debt to Equity NXTC|Current Liabilities to Capital Leap Therapeutics|Intensity Therapeutics Inc - Short-Term Debt to Equity Ratio|Short-Term Indebtedness to Equity Sensei Bio (SNSE)|Short-Term Debt to Equity Ratio Synthetic Biologics|Short-Term Loans to Capital Ratio gritstonebio.com (GRTS)|Short-Term Debt to Capital Kineta, Inc.|Ratio of Short-Term Indebtedness to Capital neximmune.com NEXI|TSBX (Turnstone Biologics Corporation) - Short-Term Debt to Capital|VCNX: Current Liabilities to Capital|Short-Term Debt to Equity Harpoon Tx HARP